Trial Profile
Phase IIa Efficacy and Safety Trial of Capadenoson in Patients With Chronic Stable Angina
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2021
Price :
$35
*
At a glance
- Drugs Capadenoson (Primary)
- Indications Angina pectoris
- Focus Therapeutic Use
- Sponsors Bayer
- 14 Aug 2008 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 14 Aug 2008 Planned initiation date changed from 1 Oct 2007 to 1 Dec 2007 as reported by ClinicalTrials.gov.
- 14 Aug 2008 Planned end date added as 1 Dec 2007 as reported by ClinicalTrials.gov.